Akums Drugs and Pharmaceutical - Asset Resilience Ratio
Akums Drugs and Pharmaceutical (AKUMS) has an Asset Resilience Ratio of 23.78% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Akums Drugs and Pharmaceutical current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2026)
This chart shows how Akums Drugs and Pharmaceutical's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Akums Drugs and Pharmaceutical total assets.
Liquid Assets Composition Over Time
This chart breaks down Akums Drugs and Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Akums Drugs and Pharmaceutical for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs12.95 Billion | 23.78% |
| Total Liquid Assets | Rs12.95 Billion | 23.78% |
Asset Resilience Insights
- Good Liquidity Position: Akums Drugs and Pharmaceutical maintains a healthy 23.78% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Akums Drugs and Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Akums Drugs and Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Akums Drugs and Pharmaceutical (2022–2026)
The table below shows the annual Asset Resilience Ratio data for Akums Drugs and Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 23.78% | Rs12.95 Billion ≈ $140.05 Million |
Rs54.47 Billion ≈ $589.07 Million |
+12.09pp |
| 2025-03-31 | 11.69% | Rs4.81 Billion ≈ $51.99 Million |
Rs41.13 Billion ≈ $444.85 Million |
+6.66pp |
| 2024-03-31 | 5.03% | Rs1.77 Billion ≈ $19.12 Million |
Rs35.16 Billion ≈ $380.28 Million |
+2.00pp |
| 2023-03-31 | 3.03% | Rs988.92 Million ≈ $10.69 Million |
Rs32.67 Billion ≈ $353.26 Million |
+1.46pp |
| 2022-03-31 | 1.57% | Rs481.56 Million ≈ $5.21 Million |
Rs30.69 Billion ≈ $331.91 Million |
-- |
About Akums Drugs and Pharmaceutical
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offe… Read more